Please login to the form below

Not currently logged in
Email:
Password:

Merck KGaA shakes up pharma leadership

Stefan Oschmann becomes deputy CEO as Belén Garijo assumes more responsibility

merck stefan oschmannMerck KGaA has made several changes to the leadership of its pharmaceutical business.

At the start of next year Stefan Oschmann (top right), current CEO for pharma, will move to a new role as deputy CEO of the entire group. He will also become vice chairman of the executive board.

Oschmann will be replaced by Belén Garijo (bottom right), current CEO of Merck's biotech division Merck Serono in a move that will expand her responsibilities, adding oversight for consumer health, allergy and biosimilars.

Johannes Baillou, chairman of the board of partners of Merck, said: “With today's management decisions we strengthen Merck's leadership team and prepare the ground for continuity to reach our ambitious growth targets until the year 2018 and beyond.”

Belén Garijo, Merck KGaAThe announced comes one year after Garijo left her role as Merck Serono's chief operating officer to replace Oschmann as CEO of the division.

Garijo's career prior to joining Merck in 2011 included a spell at Sanofi, where she led global integrations of the company's acquisition of Genzyme.

Oschmann also joined Merck in 2011, having spent the previous 11 years at its US-based namesake Merck & Co, known as MSD outside the US and Canada.

19th September 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....